The Board of Directors of AroCell AB (publ) have decided to apply for listing of the company shares to trading on the Nasdaq First North exchange, and thereby change market for share listing.
The change of market listing is planned to take place at the turn of the month June/July 2016, and the first date for trading will be announced after approval from the Nasdaq First North exchange.
“The assessment of the Board and Management is that Nasdaq First North is a market exchange that will provide a broader exposure of the company to more groups of investors and institutions. It will also provide better opportunities for foreign investors to trade in company shares by means of the more international profile and accessibility of the Nasdaq First North exchange”, says AroCell CEO Jan Stålemark.
Redeye AB has been appointed as advisor in connection with the change of market listing.
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com . AroCell (AROC) is listed at AktieTorget and has about 2 800 shareholders.